Correlations between soluble α/β forms of amyloid precursor protein and Aβ38, 40, and 42 in human cerebrospinal fluid (original) (raw)

Free PDF

Neuroinflammation in Lyme neuroborreliosis affects amyloid metabolism Cover Page

Cerebrospinal Fluid Biomarkers of Alzheimer’s Disease: Current Evidence and Future Perspectives

Brain Sciences

Alzheimer’s disease is a progressive, clinically heterogeneous, and particularly complex neurodegenerative disease characterized by a decline in cognition. Over the last two decades, there has been significant growth in the investigation of cerebrospinal fluid (CSF) biomarkers for Alzheimer’s disease. This review presents current evidence from many clinical neurochemical studies, with findings that attest to the efficacy of existing core CSF biomarkers such as total tau, phosphorylated tau, and amyloid-β (Aβ42), which diagnose Alzheimer’s disease in the early and dementia stages of the disorder. The heterogeneity of the pathophysiology of the late-onset disease warrants the growth of the Alzheimer’s disease CSF biomarker toolbox; more biomarkers showing other aspects of the disease mechanism are needed. This review focuses on new biomarkers that track Alzheimer’s disease pathology, such as those that assess neuronal injury (VILIP-1 and neurofilament light), neuroinflammation (sTREM2...

Free PDF

Cerebrospinal Fluid Biomarkers of Alzheimer’s Disease: Current Evidence and Future Perspectives Cover Page

The effects of different familial Alzheimer's disease mutations on APP processing in vivo

Alzheimer's research & therapy, 2017

Disturbed amyloid precursor protein (APP) processing is considered to be central to the pathogenesis of Alzheimer's disease (AD). The autosomal dominant form of the disease, familial AD (FAD), may serve as a model for the sporadic form of AD. In FAD the diagnosis of AD is reliable and presymptomatic individuals carrying FAD mutations can give valuable insights into the earliest stages of the disease where therapeutic interventions are thought to be the most effective. In the current cross-sectional study, products of APP processing (e.g., sAPPα, sAPPβ, Aβ38, Aβ40 and Aβ42) were measured in the cerebrospinal fluid (CSF) of individuals carrying one of three FAD mutations, APPswe (p.KM670/671NL), APParc (p.E693G) and PSEN1 (p.H163Y), as well as in non-mutation carriers from the same families. We observed pathological APP processing in presymptomatic carriers of FAD mutations, with different profiles of APP and Aβ isoforms in the three mutation carrier groups, APPswe (p.KM670/671NL)...

Free PDF

The effects of different familial Alzheimer's disease mutations on APP processing in vivo Cover Page

Free PDF

Current state of Alzheimer’s fluid biomarkers Cover Page

Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease

Alzheimer's Research & Therapy, 2011

ABSTRACT: Autosomal-dominant Alzheimer's disease has provided significant understanding of the pathophysiology of Alzheimer's disease. The present review summarizes clinical, pathological, imaging, biochemical, and molecular studies of autosomal-dominant Alzheimer's disease, highlighting the similarities and differences between the dominantly inherited form of Alzheimer's disease and the more common sporadic form of Alzheimer's disease. Current developments in autosomal-dominant Alzheimer's disease are presented, including

Free PDF

Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease Cover Page

Free PDF

Transmembrane Amyloid-Related Proteins in CSF as Potential Biomarkers for Alzheimer’s Disease Cover Page

The Potential Use of Blood, Cerebrospinal Fluid, Saliva and Urine as Biological Samples for the Diagnosis of Alzheimer’s Disease

International Journal of Biochemistry Research & Review

Background and Aim: Alzheimer’s disease (AD) is the most common cause of dementia. 80% of all dementia is due to AD. Diagnosis of AD is a difficult task, as the accurate diagnosis requires post-mortem examination of brain autopsy samples. Diagnosis of AD in living individuals can be aided by the establishment of the clinical criteria, positron emission tomography (PET) examination, and biomarkers. The study of biomarkers for diagnosis of AD could help clinicians to evaluate individuals at risk, and confirm the occurrence as well as the progression of AD in a non-invasive manner. High sensitivity and high specificity of the used markers are mandatory criteria for these biomarkers to trusted for AD diagnosis and prognosis. So, this review article aims to focus on the potential use of body fluids as a source of the biomarkers that are used for investigating patients with AD. Methodology: In the current study, we reviewed scientific articles that discuss AD pathogenesis and diagnosis of...

Free PDF

The Potential Use of Blood, Cerebrospinal Fluid, Saliva and Urine as Biological Samples for the Diagnosis of Alzheimer’s Disease Cover Page

Free PDF

Cerebrospinal Fluid Biomarkers of Alzheimer's Disease in Chinese Patients: A Pilot Study Cover Page

Free PDF

Amyloid β 38, 40, and 42 species in cerebrospinal fluid: More of the same? Cover Page

Free PDF

Cerebrospinal Fluid Aβ40 Improves the Interpretation of Aβ42 Concentration for Diagnosing Alzheimer’s Disease Cover Page